SEC Form 4 FORM 4	UNI	TED STAT					ANG	Е СОМ	MISSION			
			Washington, D.C. 20549							OMB APPROVAL		
to Section 16. Form 4 or Form 5			IT OF CHANGES IN BENEFICIAL OWNERS pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940						RSHIP	Estimated average burden		
<ul> <li>obligations may continue. See Instruction 1(b).</li> </ul>	hours per response: 0.5											
1. Name and Address of Reporting Person <sup>*</sup> CRAVES FRED B			2. Issuer Name and Ticker or Trading Symbol <u>MADRIGAL PHARMACEUTICALS</u> , <u>INC.</u> [ MDGL ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner			
(Last) (First) C/O BAY CITY CAPITAL LLC 750 BATTERY STREET, SUIT	· ·		3. Date of Earliest Transaction (Month/Day/Year) 08/17/2020						Officer (give title Other (specify below) below)			
(Street) SAN FRANCISCO	94111		4. If Amendment, Date of Original Filed (Month/Day/Year)						<ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>			
(City) (State)	(Zip)					<u></u>			·			
la	uble I -		ive Securities /		red,		-		-			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, ) if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			
Common Stock		08/17/2020		s		12,500	D	\$110.73	60,375	I	See Footnotes <sup>(1)(2)</sup>	
Common Stock		08/18/2020		S		10,197	D	\$110.03	50,178	I	See Footnotes <sup>(1)(2)</sup>	
Common Stock		08/19/2020		S		7,303	D	\$107.64	42,875	I	See Footnotes <sup>(1)(2)</sup>	
Common Stock									3,729,141	I	See Footnotes <sup>(1)(3)</sup>	
Common Stock									81,380	I	See Footnotes <sup>(1)(4)</sup>	
Common Stock									281,683	D		
Common Stock									90,000	I	See Footnote <sup>(5)</sup>	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3A. Deemed Execution Date, if any (Month/Day/Year) 7. Title and 1. Title of 3. Transaction 5. Number 6. Date Exercisable and 8. Price of 9. Number of 10. 11. Nature Conversion Transaction Code (Instr. Ownership Derivative Date Expiration Date (Month/Day/Year) Amount of Derivative derivative of Indirect (Month/Day/Year) Derivative Securities Security or Exercise Security Securities Form: Beneficial (Instr. 3) Price of Derivative 8) Securities Acquired Underlying (Instr. 5) Beneficially Direct (D) Ownership or Indirect (Instr. 4) Derivative Owned (I) (Instr. 4) Security (A) or Disposed Security (Instr. 3 and 4) Following Reported of (D) (Instr. 3, 4 and 5) Transaction(s) (Instr. 4) Amount or Number Date Exercisable Expiration Date of Shares Code v (A) (D) Title

## Explanation of Responses:

1. Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Co-Investment IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

2. These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

3. These securities are held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

4. These securities are held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. 5. Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.

Remarks:

## /s/ Fred B. Craves

<u>08/19/2020</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). \*\* Signature of Reporting Person Date

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.